1. Introduction {#sec1}
===============

*Klebsiella pneumoniae* is a member of the ESKAPE group (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species) and the Gram-negative leading bacterium in hospital acquired-infections (HAIs) \[[@bib1], [@bib2]\]. It was considered to be the most important causal agent of community-acquired infections; but in the early 1970s the epidemiology and infections spectrum dramatically changed when this bacterium was established in the hospital environment. This pathogen has developed increasing resistance to carbapenems, the last resort antibiotics typically used to treat multidrug resistant strains in hospital patients. Regretfully, now carbapenem resistant *K. pneumoniae* isolates are resistant to almost all available antibiotics and is associated with high rates of mortality [@bib3].

The hypermucoviscous *K. pneumoniae* isolates differ from classical mucosal strains because they present a positive string test. Since these *K. pneumoniae* variant were reported, hypermucoviscosity had been associated with hypervirulent strains; then new evidence has suggested that hypermucoviscosity and hypervirulence are two different phenotypes that should not be used synonymously regardless of whether they can act in synergy under certain circumstances [@bib4].

Pathogenic *K. pneumoniae* strains have the potential to cause a wide variety of infectious diseases, including urinary tract, respiratory tract and blood infections [@bib5]. Some virulent factors have been described codifying for capsule (*magA*, *k2A*, *wcaG*), hypermucoviscosity-associated gene A specific to K1 capsule serotype (*magA*, *rpmA*), adhesins (*fimH*, *mrkD*, *kpn*), lipopolysaccharides (*wabG*, *uge*, *ycfM*), iron acquisition systems (*iutA*, *iroN*, *entB*) and other virulence factors (*allS*, *hly*, *cnf-1*) that enable them to overcome host defenses, although it is not clear the linkage of these genes with antibiotic resistance [@bib6].

Carbapenem hydrolysing β-lactamases have been reported to be increasingly widespread. Ambler molecular class A (KPC), class B (VIM, IMP, NDM) and class D (OXA-48) types are the most frequently found in *K. pneumoniae* causing serious nosocomial infections [@bib7]. In South America, carbapenemase-producing *K. pneumoniae* was initially reported in 2006 in Colombia [@bib8] and after in Brazil and Argentina \[[@bib9], [@bib10]\]. The hospital-acquired high-risk clones sequence types (ST) ST258 and ST11 were worldwide disseminated [@bib11], whereas the Latin America local epidemiology pointed out to ST11 and ST437 associated to *bla*~KPC-2~ and *bla*~KPC-3~ production \[[@bib12], [@bib13]\]. In reference to our country, Argentina, previous studies demonstrated that the emergence of *bla*~KPC-2~ is also associated with CC258 [@bib14].

The aim of this study was to determine the clinical, epidemiological and molecular patterns of hypermucoviscous carbapenem-resistant *K. pneumoniae* isolates causing nosocomial infections at a tertiary referral hospital in Tucumán, Argentina.

2. Materials and methods {#sec2}
========================

2.1. Study design {#sec2.1}
-----------------

This retrospective study was conducted in a teaching hospital in Tucumán, Argentina (500 beds) with approximately 3000 admissions/day. Over a period of 6 months, from May 1 to October 31, 2014, all patients suffering from *K. pneumoniae* infections, resistant to carbapenemes and hospitalized for more than 48 hours were studied; patients from other hospitals or with community-acquired infections or without strict infection criteria were not included in this study. After the patients signed an informed consent, the clinical history was accessed and the clinical-epidemiological information was registered: name and surname, age, sex, time of hospitalization prior to isolation, hospital stay, comorbidities, probable site of the acquisition of the infection, type of infection and antibiotic treatment used. Institutional activity data (number of admissions and mean length of stay) of this period were collected by the hospital for the calculation of incidence rates. The ethics committee of the Ángel C. Padilla hospital approved the study and authorized the access to clinical information.

2.2. Identification and Antimicrobial Susceptibility Testing {#sec2.2}
------------------------------------------------------------

Bacterial identification was confirmed by MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight) (Microflex LT, Bruker Daltonics, Bremen, Germany), susceptibility patterns were determined by the automated Vitex 2® system (BioMerieux, Merci l\'Etoile, France) [and]{.ul}????? by broth microdilution method including ampicillin (AMP), ampicillin/sulbactam (SAM), piperacillin/tazobactam (PTAZ), cephalothin (CEF), cefotaxime (CTX), ceftazidime (CAZ), cefepime (FEP), meropenem (MER), imipenem (IMP), gentamicin (GEN), amikacin (AKN), colistin (COL), trimethoprim/sulfamethoxazole (TMS) and ciprofloxacin (CIP). Breakpoints were defined following the document M100-S24 of the Clinical and Laboratory Standards Institute [@bib15]. Susceptibility to tigecycline was determined by broth microdilution method and for fosfomycin by agar dilution method with glucose-6-phosphate (25 mg/L in the medium). Breakpoints were defined according to the Committee on Antimicrobial Susceptibility Testing (EUCAST) [@bib16]. Synergy tests with boronic acid and EDTA disks close to the carbapenemes and the modified Hodge test (MHT) were performed for the detection of carbapenemases [@bib17]. *K. pneumoniae* ATCC700603 and *Eschercihia coli* ATCC 25922 were used as quality control strains for the antibiotic susceptibility tests.

2.3. Detection of the hypermucoviscous phenotype {#sec2.3}
------------------------------------------------

All carbapenem-resistant *K. pneumoniae* isolates were grown in nutritive agar (Britania®) enriched with 5% defibrinated blood, Mac Conkey agar (Britania®) and CLED agar (Britania®). Hypermucoviscosity phenotype was defined by the formation of a viscous filament ≥5 mm after stretching a colony with a loop on all the agar plates tested \[[@bib18], [@bib19]\].

2.4. Strain selection {#sec2.4}
---------------------

All the hypermucoviscous *K. pneumoniae* strains were selected on the basis of MIC values of ≥2 mg/liter for any of the carbapenems imipenem, meropenem or ertapenem and synergy and Hodge tests positive.

2.5. β-lactamases molecular characterization {#sec2.5}
--------------------------------------------

DNA extracts were prepared by boiling the bacterial suspensions [@bib20]. Multiplex PCR targeting carbapenemase genes (*bla*~KPC~, *bla*~NDM~, *bla*~VIM~ and *bla*~OXA-48~) and extended spectrum β-lactamases-ESBLs: SHV variants including SHV-2 (*bla*~SHV-2~) and CTX-M variants including CTX-M-2 (*bla*~CTX-M-2~) were performed [@bib21]. The amplicons were sequenced with ABI3130CL (Applied Biosystems, USA) and the sequences were analyzed on the National Center for Biotechnology Information (NCBI) [@bib22]. The complete CDS of the β-lactamases detected has not been determined and the indicated allelic variant has been obtained from partial sequences.

2.6. Analysis of virulence gene regions {#sec2.6}
---------------------------------------

The virulence genes were detected in four-separated multiplex PCR reactions (*magA*-*fimH*-*uge*-*iutA, wabG*-*rmpA*-*cnf1*-*ycfM*, *hly*-*iroN-k2A*-*mrkD*, and *kpn-allS-entB-wcaG*) with the following thermal cycling conditions: 5 minutes of pre-denaturation at 95 °C, followed by 30 cycles: 1 minute at 94 °C, 1 minute at 58 °C, 1 minute at 72 °C and 10 minutes of final elongation at 72 °C (Sensoquest Labcycler, Germany) [@bib6].

2.7. Population structure {#sec2.7}
-------------------------

Molecular typing was performed by pulsed-field electrophoresis (PFGE) and Multilocus Sequence Typing (MLST). Isolates were typed by PFGE of *Spe*I-digested total genomic DNA (TaKaRa, Tokyo, Japan), and the DNA fragments were separated by electrophoresis on 1 % SeaKeam Gold agarose (Lonza, Rockland, ME, United States) in 0.5X TBE (45 mM Tris, 45 mM boric acid, 1.0 mM EDTA; ph 8.0) buffer using the CHEF Mapper XA PFGE system (Bio-Rad, United States) at 6 V/cm^2^ and 14 °C, with alternating pulses at a 120° angle in a 5--20 s pulse time gradient for 19 h. DNA patterns were interpreted according to Tenover *et al* [@bib23]. Strains were considered to be the same clone (type) if they showed ≥75% genetic identity, or fewer than three fragment differences on the PFGE profiles. Subsequently one isolate for each PFGE pulsotype was submitted to MLST technique following the *K. pneumoniae* MLST website guidelines [@bib24].

3. Results {#sec3}
==========

A total of 35 patients, which their clinical-epidemiological characteristics are shown on [Table 1](#tbl1){ref-type="table"}, infected by carbapenem-resistant *K. pneumoniae* were identified. Patients were admitted in a range of 3--74 days previous to the carbapenem-resistant *K. pneumoniae* detection. The sample sources were the respiratory tract (n = 12, 34.2%), urinary tract (n = 12, 34.2%), soft tissue (n = 5, 14.2%), blood (n = 2, 5.7%), cerebrospinal fluid (n = 2, 5.7%) bone (n = 1, 2.8%), and abdominal fluid (n = 1, 2.8%).Table 1Clinical-epidemiological characteristics of 35 patients included in the study.Table 1Population CharacteristicsPatients number (%)**Male sex**22 (62.8%)**Comorbilities**Diabetes6 (17.1%)Neoplasia4 (11.4%)Cronic renal insuffiency3 (8.5%)Reumathoid disease2 (5.7%)No Comorbilities20 (57.1%)**Site of adquisition**Intensive care unit16 (45.7%)Room 36 (17.1%)Surgery6 (17.1%)Room 101 (2.9%)Room112 (5.7%)Intermediate care unit2 (5.7%)Room 81 (2.9%)Room 71 (2.9%)**Type of infection**Urinary tract infection11 (31.4%)Surgery wound infection5 (14.2%)Respiratory tract infection10 (28.5%)Intra-abdominal infection5 (14.2%)catheter-related infections1 (2.8%)Osteoarticular infections2 (5.7%)Bacteremia1 (2.8%)**Antibiotics used**[a](#tbl1fna){ref-type="table-fn"}Amikacin27 (77.1)Ciprofloxacin4 (11.4)Colistin25 (71.4)Imipenem14 (40.0)Meropenem11 (31.2)piperacillin/tazobactam29 (82.8)Vancomycin2 (5.71)[^1]

All 35 isolates were multidrug resistant, have similar susceptibility profiles ([Table 2](#tbl2){ref-type="table"}), and carried the *bla*~KPC-2~ gene. In 16 isolates (45.7%) the *bla*~CTX-M-2~ gene was also amplified, as well as *bla*~SHV-2~ in 10 isolates (28.6%) and *bla*~CTX-M-2~*/bla*~SHV-2~ in 5 isolates (14.3%). Virulence factors carriage were as follows: adhesins (97.1%), siderophores (94.3%) and phagocytosis resistance (74.3%) ([Table 3](#tbl3){ref-type="table"}). The capsular serotype K2 was identified in 68.6% of the isolates, and in the remaining isolates the tipification was not possible.Table 2Susceptibility testing and minimum inhibitory concentration (MIC) results of 35 CRKP isolates.Table 2Antimicrobial agentMIC rangeMIC50 (mg/L)MIC90 (mg/L)Number of S (%)Ampicillin≥32≥32≥320 (0)Ampicillin/Sulbactam≥32≥32≥320 (0)Piperacillin/Tazobactam16-≥128≥128≥1280 (0)Cefalotin≥64≥64≥640 (0)Cefotaxime≤1-≥64≥64≥643 (1)Ceftazidime4-≥64≥16≥1611 (31)Cefepime≤1-≥64≥16≥1624 (68)Meropenem≥16≥16≥160 (0)Imipenem8-≥16≥16≥160 (0)Gentamicin≤1-≥16≥16≥168 (22)Amikacin≤2-16≤2≤235 (100)Colistin≤0.5≤0.5≤0.535 (100)Tigecycline[a](#tbl2fna){ref-type="table-fn"}0.25--10.50.533 (94)Fosfomycin intravenous\<32-64\<32\<3234 (97)Trimethoprim/Sulfametoxazole≤20-≥320≥320≥32011 (31)Ciprofloxacin≤0.25--32110 (0)[^2][^3]Table 3Carbapenem resistance and virulence gene profiles of *K. pneumoniae* strains.Table 3ST/Capsular TypeStrainClinical sourcesCarbapenemase, ESBL[a](#tbl3fna){ref-type="table-fn"}Virulence gene profilesST25/K21BoneKPC-2, CTX-M-2*uge,wabG,ycfM,iroN,mrkD,kpn,entB*3PurulentKPC-2, CTX-M-2*uge,iroN,mrkD,kpn,entB*4UrineKPC-2, CTX-M-2*uge,ycfM,iroN,mrkD,kpn,entB*6UrineKPC-2, CTX-M-2*uge,wabG,ycfM,iroN,mrkD,kpn,entB*7LCRKPC-2*uge,mrkD,kpn,entB*9PurulentKPC-2, CTX-M-2*uge,wabG,ycfM,iroN,kpn,entB*10PurulentKPC-2*uge,wabG,iroN,kpn,entB*21BalKPC-2, CTX-M-2*uge,ycfM,mrkD,kpn,entB*26UrineKPC-2, CTX-M-2, SHV-2*mrkD,kpn,entB*27BalKPC-2, CTX-M-2, SHV-2*ycfM,mrkD,kpn,entB*28UrineKPC-2, CTX-M-2, SHV-2*ycfM,mrkD,kpn,entB*35BalKPC-2, CTX-M-2*uge,wabG,ycfM,iroN,mrkD,kpn,entB*36BalKPC-2, CTX-M-2*uge,wabG,ycfM,iroN,kpn,entB*S25/NT17AbdominalKPC-2, CTX-M-2*ycfM,kpn,entB*ST17/K28BalKPC-2, CTX-M-2*uge,ycfM,iroN,mrkD,kpn,entB*ST17/NT15UrineKPC-2, SHV-2*uge,wabG,ycfM,kpn,entB*23BalKPC-2, SHV-2*kpn*24UrineKPC-2, CTX-M-2*kpn,etnB*25BloodKPC-2, CTX-M-2*mrkD,kpn,entB*ST629/K216BalKPC-2*wabG,ycfM,mrkD,kpn,entB*30BalKPC-2, SHV-2*uge,wabG,ycfM,iroN,mrkD,kpn,entB*34BalKPC-2*ycfM,kpn,entB*ST629/NT38PurulentKPC-2, SHV-2*uge,kpn,entB*ST995/K211UrineKPC-2, CTX-M-2*uge,mrkD,kpn,entB*ST147/NT12LCRKPC-2, SHV-2*uge,kpn,entB*37BalKPC-2, SHV-2*uge,mrkD,kpn,entB*ST258/K220UrineKPC-2, CTX-M-2*mrkD,kpn,entB*ST268/K214UrineKPC-2, CTX-M-2, SHV-2*uge,mrkD,kpn,entB*ST133/K239BalKPC-2, SHV-2*mrkD,kpn,entB*ST111/NT40BloodKPC-2, CTX-M-2, SHV-2*uge,kpn,entB*ST551/NT41BalKPC-2, CTX-M-2*entB*Clon A/K213UrineKPC-2, SHV-2*kpn,etnB*Clon B/K222UrineKPC-2, SHV-2*uge,iutA,ycfM,mrkD*Clon C/NT32UrineKPC-2, CTX-M-2*uge,wabG,iroN,kpn,entB*Clon D/K233PurulentKPC-2, SHV-2*uge,wabG,ycfM,iroN,mrkD,kpn,entB*[^4][^5]

We identified a total of 20 PFGE pulsotypes (PT) grouped into different clusters (A-S), corresponding to 10 STs, ST25 was the most represented clone, followed by ST629, ST17, ST147, ST268, ST258, ST11, ST111, ST133, ST551 and 4 isolates with allelic combinations not previously documented ([Table 3](#tbl3){ref-type="table"}, [Fig. 1](#fig1){ref-type="fig"}). The overall incidence of KPC-2 *K. pneumoniae* reported by the hospital was 0.290 per 1000 admissions.Fig. 1DNA finger printing by PFGE and relation to ST type in KPC-2 *Klebsiella pneumoniae* strains.Fig. 1

4. Discussion {#sec4}
=============

The rapid spread of KPC-producing *K. pneumoniae* is a major clinical and public health concern and continue epidemiological surveillance is necessary. These broad-spectrum β-lactamases are increasing in new locations worldwide, indicating an ongoing process \[[@bib25], [@bib26]\]. The Pan American Health Organization (PAHO) reports that Argentina is one of the countries with the most "pandrug resistant\" nosocomial isolations of Latin America [@bib27]. Besides the numerous efforts made at local or national level to control the spread of these species, the rapid dissemination of carbapenem-resistant *K. pneumoniae* constituted a clinically relevant problem of our region. Tucuman is situated, in the north of Argentine (NOA), within a multi border area limiting with Bolivia, Chile and Paraguay. Since 2006 an active monitoring for carbapenem-resistant *K. pneumoniae* detection is carried out in our Department.

The present study is focused on the molecular characterization of carbapenem-resistant hypermucoviscous *K. pneumoniae*. The incidence rate of these strains in our institution was 0.290 per 1000 admissions, higher than the rate registered in Belgium where the average incidence among 9 hospitals was 0.223 per 1000 admissions [@bib28] and even greater than in Germany where it is significantly lower (0.047 per 1000 admissions) [@bib29]. The average time of hospitalization prior to the acquisition of the infection was 30 days, denoting the high hospital stay; the Intensive Care Unit was the most common site of acquisition, in line with previous reports \[[@bib26], [@bib30], [@bib31], [@bib32], [@bib33]\]. Unlike other studies, the urinary and respiratory tract was the most common sources of clinical samples (34.2%), followed by soft tissue (14.2%) and blood (5.7%), while other authors reported bacteremia as the leading site of infection \[[@bib34], [@bib35]\].

Antimicrobial susceptibility testing confirmed resistance to piperacillin/tazobactam, ciprofloxacin and meropenem in all isolates, higher than the results found in Belgian hospitals: 43.9%, 80.3% and 53% respectively. The resistance proportion for tigecycline and colistin was still lower with only 2 and 1 strain respectively [@bib28].

Focusing on the molecular and genetic characterization, we found Extended spectrum β-lactamases (ESBLs) genes as *bla*~CTX-M-2\ (~45.7%), *bla*~SHV-2~ (28.6%) and *bla*~CTX-M-2~/*bla*~SHV-2~ (14.3%). These results differ from that described by Canton *et al.* reporting of *bla*~CTX-M-9~ in 96% of the isolates, whereas only 1% contained the *bla*~CTXM-15~ gene, which is by far the most prevalent CTX-M variant worldwide [@bib36].

KPC-2 is the most prevalent carbapenemase in China, with rare detection of metallo-carbapenemases, the same as other Latin American countries that present *bla*~KPC-2~ and *bla*~KPC-3~ in agreement with our results. However, some other countries may have another dominant carbapenemases; for example, the United Kingdom is likely to have a mixed carbapenemase pattern with VIM and NDM, and NDM types followed by OXA-48-like types were prevalent in India \[[@bib37], [@bib38]\].

Molecular typing of our strains showed a clonal dissemination of ST25 and ST17, whereas other Latin America studies reported ST11 and ST437 associated with the spread of *bla*~KPC-2~ and *bla*~KPC-3~ \[[@bib9], [@bib39], [@bib40]\]. Previous studies located in Argentina described ST258 as the dominant clonal type [@bib14]. The importance of ST25-CC65 was previously described by Brisse *et al.* [@bib41].

Since the presence of hypermucoviscous variants of *K. pneumoniae* in the world, many cases of invasive infections caused by these pathogens were described. Nevertheless, today the terms hypermucoviscous and hypervirulent are different and genes associated with the virulence must be determined [@bib4]. Although in hypervirulent strains the K1 and K2 capsular types were the most exhaustively described, it has been demonstrated that *K. pneumoniae* producing infection and non-hypervirulent strains can also showed the K2 serotype [@bib42]. Our isolates showed a K2 serotype associated with different genetic lineages in coincidence with Zhao *et al.* that also demonstrated the K2 serotype in 68.7% of the hypermucoviscosity-positive *K. pneumoniae* isolates [@bib43].

Isolates containing the *mag*A, *cnf*-1, *hly* and *allS* genes were not detected in coincidence with Aksöz *et al.* In this study, capsule associated genes were *wabG* (48.5%), *uge* (80%), and *ycfM* (57.1%), encoding capsule, lipoprotein, and external membrane protein, respectively. These results are consistent with previous studies reporting *wab*G (in 88% of isolates), *uge* (86%), *ycf*M (80%) and entB (72%) [@bib6]. According to the distribution of virulence genes 16 virulence profiles/35 CRKP strains were defined according with Aksöz *et al.*, who described 29 virulence profiles/34 CRKP strains. This situation evidences the high possibilities of virulence factors combination, forcing the molecular typing at individual isolates level.

The studied strains express two types of fimbrial adhesins; type 1 and type 3 fimbriae [@bib5]. While type 1 fimbriae, encoding *fim*H, play an important role in urinary tract infections caused by these strains, type 3 fimbriae, encoding *mrk*D, promote biofilm development [@bib44]. Besides it, siderophores encoding *ent*B, *iut*A and *iro*N, are iron binding proteins and they also promote biofilm formation \[[@bib45],[@bib46]\]. In this study, total fimbrial adhesins (*fim*H, *mrk*D and *kpn*) were observed in 34 isolates (97.1%) and siderophores (*ent*B and *iro*N) in 33 isolates (94.2%) similar as were observed by other authors that described total fimbrial adhesins in 42 strains (84%) and siderophores (*ent*B and *iro*N) in 40 isolates (80%). This situation shows that these virulence factors are important for *Klebsiella* pathogenicity. It is interesting to note that two strains, 23 and 41, have a single virulence factor: *kpn* and *ent*B*,* respectively.

In summary, we reported an epidemic scenario of hypermucoviscous *bla*~KPC-2~ producing ST25 and ST17 *K. pneumoniae* from a single hospital in Tucuman, Argentina. This study reinforces the needed of continues surveillance to prevent a major dissemination of ST25-CC65.
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[^1]: All antibiotics mentioned were combined in different therapeutic schemes.

[^2]: S Susceptible strains.

[^3]: Interpreted according to EUCAST clinical breakpoints for *E. coli*.

[^4]: References: genes associated with the resistance to phagocytosis (*uge, ycfM, wabG*), adhesins (*mrkD, kpn*), capsular elements (*magA, k2A*), iron adquisition systems (*entB, iroN*), associated with the celular wall (*WabG*), and others virulence factors (*allS*). K2: capsular antigen 2. NT: non-typable. Bal: bronchoalveolar lavage. LCR: cerebrospinal fluid. ESBL: extended spectrum β-lactamases.

[^5]: The complete CDS of the β-lactamases detected has not been determined and the indicated allelic variant has been obtained from partial sequences.
